Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 21,700 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 21,700 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $24.18, for a total value of $524,706.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Anish Patel also recently made the following trade(s):

• On Friday, October 18th, Anish Patel sold 716 shares of Enliven Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $21,480.00.

Enliven Therapeutics Stock Performance

ELVN traded down $2.41 on Friday, hitting $21.74. The company had a trading volume of 323,088 shares, compared to its average volume of 204,598. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -11.44 and a beta of 1.04. The stock has a fifty day moving average price of $24.66 and a 200-day moving average price of $24.39. Enliven Therapeutics, Inc. has a 12-month low of $10.90 and a 12-month high of $30.03.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Quest Partners LLC boosted its holdings in Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after acquiring an additional 742 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Enliven Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock worth $232,000 after purchasing an additional 3,559 shares during the last quarter. SG Americas Securities LLC acquired a new position in Enliven Therapeutics during the 3rd quarter valued at approximately $256,000. Verition Fund Management LLC acquired a new stake in shares of Enliven Therapeutics during the third quarter worth $271,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Enliven Therapeutics during the second quarter worth $322,000. Institutional investors own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ELVN shares. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. Robert W. Baird upped their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, November 15th. Finally, BTIG Research initiated coverage on Enliven Therapeutics in a research report on Friday, December 13th. They set a “buy” rating and a $42.00 target price for the company. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $38.25.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.